Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis.
Quick Facts
What This Study Found
Tirzepatide 15 mg reduced glycated hemoglobin by 93.5% and body weight by 99.7% compared to insulin.
Key Numbers
How They Did This
The study utilized a Bayesian network meta-analysis of randomized controlled trials (RCTs) to compare tirzepatide with other diabetes treatments.
Why This Research Matters
These findings suggest that tirzepatide could be a more effective option for managing type 2 diabetes, potentially improving patient outcomes. Understanding its safety profile is crucial for healthcare providers.
What This Study Doesn't Tell Us
The study calls for more well-designed RCTs to further evaluate tirzepatide's clinical performance and its cardiovascular benefits.
Trust & Context
- Original Title:
- Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis.
- Published In:
- Frontiers in pharmacology, 13, 998816 (2022)
- Authors:
- Guan, Ruifang, Yang, Qing(4), Yang, Xiaolei, Du, Wandi, Li, Xuening, Ma, Guo
- Database ID:
- RPEP-06157
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06157APA
Guan, Ruifang; Yang, Qing; Yang, Xiaolei; Du, Wandi; Li, Xuening; Ma, Guo. (2022). Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis.. Frontiers in pharmacology, 13, 998816. https://doi.org/10.3389/fphar.2022.998816
MLA
Guan, Ruifang, et al. "Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis.." Frontiers in pharmacology, 2022. https://doi.org/10.3389/fphar.2022.998816
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and safety of tirzepatide in patients with type 2 d..." RPEP-06157. Retrieved from https://rethinkpeptides.com/research/guan-2022-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.